SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Never Hibernate who wrote (26884)4/5/1999 3:33:00 PM
From: Clayleas  Respond to of 122087
 
News on ENMD is shown here:
Message 8712979



To: Never Hibernate who wrote (26884)4/5/1999 3:37:00 PM
From: Force Majeure  Respond to of 122087
 
NH,

Thanks. I just read the heart disease rumor, and am continuing to keep a very close eye on this one.

Cheers,

FM



To: Never Hibernate who wrote (26884)4/5/1999 3:46:00 PM
From: surelock  Respond to of 122087
 
I don't think the rumors will mean too much if anyone bothers
to read the whole release. This is near the bottom:

At EntreMed Inc. in Rockville, Md., which is developing endostatin,
spokeswoman Mary P. Sundeed said the company is concentrating on the cancer uses
of the drug and has no plans to test it against heart disease.

Inititiating a position now at $24 or better.

SH


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News